

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/132933 A1

(43) International Publication Date
23 June 2022 (23.06.2022)

(51) International Patent Classification:

A61K 31/15 (2006.01) *A61K 31/506* (2006.01)
A61K 31/4178 (2006.01) *A61K 31/51* (2006.01)
A61K 31/4196 (2006.01) *A61K 45/06* (2006.01)
A61K 31/496 (2006.01) *A61P 35/02* (2006.01)

(21) International Application Number:

PCT/US2021/063563

(22) International Filing Date:

15 December 2021 (15.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/126,289 16 December 2020 (16.12.2020) US

(71) Applicant: **IMPACT BIOMEDICINES, INC.** [US/US];
86 Morris Avenue, Summit, New Jersey 07901 (US).

(72) Inventors: **KRISHNA, Gopal**; 86 Morris Avenue, Summit, New Jersey 07901 (US). **OGASAWARA, Ken**; 86 Morris Avenue, Summit, New Jersey 07901 (US).

(74) Agent: **COVERT, John M.** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: DOSING OF FEDRATINIB

(57) Abstract: The present disclosure provides methods of treating myeloproliferative disorders in patients concurrently receiving a dual CYP2C19 and CYP3A4 inhibitor.



WO 2022/132933 A1